UNION to present Phase 2b orismilast results in dermatitis at EADV 2024

UNION therapeutics A/S, a clinical-stage pharmaceutical company based in Hellerup, Denmark, announced that the results of their ADESOS Phase 2b study with orismilast in atopic dermatitis (AD) have been selected for a late-breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) Congress 2024 in Amsterdam from September 25-28, 2024.

Orismilast, a next-generation high-potency PDE4B/D selective inhibitor, has shown promising results in various clinical trials, including psoriasis and hidradenitis suppurativa (HS). It is currently under evaluation in an ongoing Phase 2 study for ulcerative colitis (UC). UNION has plans to advance orismilast to Phase 3 development in AD.

Prof. Dr. Eric Simpson will present the new data from the ADESOS Phase 2b study of orismilast in AD. The presentation will cover the efficacy and safety results from this trial. Additionally, two posters will be presented: one focusing on the molecular effects in the skin of AD patients after oral orismilast treatment and another detailing the overall efficacy and safety of orismilast in this patient population.

Dr. Simpson emphasized the unmet need for safe and effective oral treatments for AD, noting the significant impact on patients' experiences of itch and pain, and lesional improvements. According to Dr. Simpson, orismilast has shown early promise in reducing itch within one week of treatment, offering a novel treatment option for AD patients.

Kim Kjøller, Co-CEO of UNION, expressed satisfaction with the selection of the Phase 2b results for a late-breaking oral presentation, highlighting the importance of the additional posters that will discuss the molecular effects in the skin following orismilast treatment. Kjøller looks forward to discussing these findings with leading experts at the conference as UNION moves towards Phase 3 development for orismilast in AD.

The presentation details are as follows:
- Title: "Orismilast efficacy in adults with moderate-to-severe atopic dermatitis in a phase 2b trial: early impact on itch and patient-reported outcomes"
- Session code: D1T01.1
- Presenter: Prof. Dr. Eric Simpson, Dermatology Professor
- Date and Time: Wednesday, September 25, 2024, at 2:30-2:45 PM GMT

Poster details include:
1. Title: "Molecular effects in the skin of atopic dermatitis after oral treatment with orismilast"
- ID: 5905
- Poster number: P3569
2. Title: "Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a Phase 2b randomized, double-blinded, placebo-controlled clinical trial (ADESOS)"
- ID: 4256
- Poster number: P0598

About Orismilast:
Orismilast is a potent PDE4 inhibitor that targets the PDE4B/D subtypes associated with inflammation. It acts early in the inflammation cascade and induces a broad range of anti-inflammatory effects across various cytokines involved in dermatological and immunological diseases. UNION is developing orismilast for oral treatment across multiple immunological conditions, including AD, HS, psoriasis, and UC. Based on the known safety profile of the PDE4 class, orismilast aims to achieve best-in-class or first-in-class positions in these diseases.

UNION has received FDA clearance for orismilast's Investigational New Drug (IND) application and Fast Track designation for the treatment of moderate to severe AD and HS.

UNION therapeutics is a privately held company led by an international team of biotech entrepreneurs and seasoned pharma executives, with a record of developing and launching over fifteen marketed drugs. The company's leading asset, orismilast, holds potential as the first safe oral treatment for AD.